抗体与药物结合物的旁观者效应:在瘤异质性的细线上进行导航
Yiming Wang1, Xi Cheng1, Xuan Li2
1Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, China.
Critical reviews in oncology/hematology
|October 8, 2025
概括
抗体-药物合物 (ADC) 的旁观者效应通过允许有效载荷杀死邻近细胞来增强癌症治疗. 优化这种效果需要平衡功效与特异性,以最大限度地降低毒性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 抗体-药物合物 (ADCs) 将单克隆抗体与细胞毒性有效载荷结合起来,用于向癌症治疗.
- 旁观者效应,即释放的有效载荷杀死抗原阴性邻近细胞,是ADC的一个关键但未被充分研究的特征.
研究的目的:
- 审查ADC旁观者效应的机制,临床影响和优化策略.
- 在ADC设计中强调旁观者功率和目标特异性之间的平衡.
主要方法:
- 文献综述综合了目前对ADC旁观者效应的理解.
- 对临床数据的分析,比较了有旁观者活动和没有旁观者活动的ADC.
- 讨论影响ADC透和有效载荷扩散的瘤微环境 (TME) 因素.
主要成果:
- 可切割的链接器,疏水的有效载荷和内部化对于旁观者活动至关重要.
- 像缺氧和结合部位障碍 (BSB) 这样的TME因素可以限制ADC透和旁观者有效性.
- 具有旁观者效应的ADC显示出优越的疗效,但引起了对非目标毒性和可变疗效的担忧.
结论:
- 与目标特异性平衡旁观者功效是必不可少的,特别是在抗原表达低或异质的瘤中.
- 未来的研究应该专注于量化体内旁观者贡献,了解有效载荷扩散的TME调节,并验证组合策略.
- 通过这些见解来改进ADC设计,将改善治疗指数,与精确瘤学目标保持一致.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:21Drug Distribution: Tissue Binding
3.8K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.8K
00:42Cross-reactivity
32.8K
Overview
32.8K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:26Antibody Actions
2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K